Clinical Trial Update: Study of Ravulizumab in Pediatric Participants With Primary IgAN [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update indicates Ravulizumab is being studied in pediatric participants with primary IgA nephropathy, including IgA vasculitis with nephr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iga Nephropathy
• Iga Vasculitis with Nephritis

Drugs mentioned

• Ravulizumab (ravulizumab)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: IgAN, IgAVN | Phase 3 | Status: RECRUITING